PRINCETON, N.J.–(BUSINESS WIRE)–Certara® the global leader in model-informed drug development,
regulatory science, real-world evidence and market access services,
announced today that it has appointed Dr. William F. Feehery as its new
Chief Executive Officer (CEO) and a member of the Certara Board of
Directors, effective June 3, 2019.
Dr. Feehery joins Certara from DuPont, where he has served since 2013 as
president of DuPont Industrial Biosciences, a $2.2 billion global
biotechnology business which experienced significant growth and
profitability under his leadership. In that role, he had full P&L
responsibility for 3,000 people, including 500 R&D staff, 20
manufacturing plants, and worldwide marketing and sales across multiple
markets. He joined DuPont in 2002 and has prior experience in venture
capital and as a consultant for the Boston Consulting Group. Dr. Feehery
also serves as a board member for West Pharmaceutical Services (NYSE:
WST), a manufacturer of packing components and delivery systems for
pharmaceutical, biotech and medical device companies.
Dr. Edmundo Muniz, who has served as Certara CEO since June 2014, will
become a member of the Certara Board of Directors and Chair of the
Board’s newly-formed Science Committee. During Dr. Muniz’ tenure as CEO,
Certara has grown to become the world leader in model-informed decision
support solutions for drug development, regulatory science and
market/patient access.
“We are very pleased to welcome Bill to Certara. Bill’s broad and
diverse background in technology and commercial operations position him
well to lead the company. We are confident that his technical,
operational and commercial expertise will serve him well as he takes the
company to its next level of growth,” said Sheri McCoy, Certara Chairman
of the Board. She went on to say that “we also want to thank Edmundo for
the great work he has done in establishing the vision and strategy that
has resulted in Certara becoming the world leader in model-informed drug
development and a critical innovator in modeling and simulation.”
“I am excited to join Certara, an exceptional company that is reducing
the cost, time, and risk of drug development. I could not have made a
better choice than to join the company at this exciting time in its
growth trajectory,” said Dr. Feehery. “Certara’s track record for
optimizing drug development and patient care decision-making by
leveraging its integrated portfolio of quantitative and in silico capabilities
is impeccable. The company has already had a significant positive
impact, helping to bring safer and more effective new therapies to
market efficiently. The healthcare field is ripe for accelerated
innovation of this type and Certara is poised to lead the market.”
Dr. Feehery holds both a PhD in chemical engineering and an MBA from
MIT. He was a Churchill Scholar at Cambridge University, and received
his BSE in chemical engineering from the University of Pennsylvania. His
doctorate, awarded while he was the recipient of a National Science
Foundation Fellowship, involved developing software and mathematical
methods for modeling complex systems.
About Certara
Certara enables superior drug development and patient care
decision-making through model-informed drug development, regulatory
science, real-world evidence solutions and knowledge integration. As a
result, it optimizes R&D productivity, commercial value and patient
outcomes. Its clients include hundreds of global biopharmaceutical
companies, leading academic institutions, and key regulatory agencies
across 60 countries. For more information, visit www.certara.com.
Contacts
Certara Contact:
Ellen Leinfuss, 609-216-9586
Chief
Corporate Affairs Officer
Media Contact:
Lisa Osborne, 206-992-5245
Rana
Healthcare Solutions
lisa@ranahealth.com